bevacizumab + 5-fluorouracil + streptozotocin

**bevacizumab + 5-fluorouracil + streptozotocin** is a three-drug combination regimen investigated for the treatment of advanced and metastatic well-differentiated pancreatic neuroendocrine tumors (pNETs). - **Bevacizumab** is a recombinant humanized monoclonal antibody that binds vascular endothelial growth factor A (VEGF-A), blocking angiogenesis and suppressing tumor blood vessel growth[1][2][4][6][8]. - **5-fluorouracil (5-FU)** is an antimetabolite small molecule that inhibits thymidylate synthase, interfering with DNA synthesis and leading to cancer cell death[3]. - **Streptozotocin** is a nitrosourea small molecule acting both as an alkylating agent and a cytotoxic compound with specificity for pancreatic cells, damaging DNA and exerting antitumor effects[3][5]. The regimen has demonstrated feasibility and activity in phase II studies for patients with progressive metastatic pancreatic neuroendocrine tumors, yielding a median progression-free survival of 23–24 months with manageable toxicities[1][5]. There is no evidence of a unique brand name or manufacturer-specific trade formulation for this exact combination.